EUVIMEDEUVIMED entdecken
Crossref

Bharangin, A Diterpenoid, Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine Through Involvement of Long Non‐Coding RNAs and Nuclear Factor‐κB

Nikee Awasthee, Anusmita Shekher, Ankit Srivastava, Subash Chandra Gupta

Clinical and Experimental Pharmacology and Physiology · 2026

DOI: 10.1111/1440-1681.70097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2026. Verfasst von Nikee Awasthee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Deoxycytidine, Pancreatic Neoplasms, Diterpenes, NF-kappa B. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Indian Council of Medical Research (ICMR), University Grants Commission, University Grants Commission of Bangladesh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PaCa) manifests as an aggressive tumour due to the late occurrence of early symptoms. The overall 5‐year survival rate of PaCa is merely 2%–9%. Bharangin (BG), a diterpenoid quinonemethide known for its anti‐cancer activities, was investigated in a preclinical PaCa model. A dose‐ and time‐dependent suppression in the viability of PaCa cells was observed by BG. The diterpenoid suppressed the level of tumorigenic proteins in PaCa cells. As evident from phosphatidylserine externalisation, acridine orange (AO)/propidium iodide (PI) staining, cell cycle analysis and DNA laddering, BG was found to induce apoptosis in PaCa cells. An accumulation in the sub‐G1 population was observed by BG. The diterpenoid induced depolarization in the mitochondrial membrane potential and enhanced the PaCa cells' sensitivity to gemcitabine (GEM). The cancer‐associated lncRNAs were also modulated by both BG and GEM in PaCa cells. BG also suppressed the p65 nuclear translocation induced by TNF‐α in PaCa cells. Overall, BG exhibits activities in PaCa cells. The suppression of NF‐κB activation and the modulation of lncRNAs expression may provide a basis for further exploration of BG as a therapeutic agent in PaCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidinePancreatic NeoplasmsDiterpenesNF-kappa BRNA, Long NoncodingGemcitabineHumansCell Line, TumorApoptosisAnimalsDrug SynergismGene Expression Regulation, NeoplasticCell SurvivalMembrane Potential, MitochondrialMice

Stichwörter der Autor:innen

bharanginchemosensitizationditerpenoidgemcitabineinflammationlong non‐coding RNApancreatic cancer

Substanzen

GemcitabineDeoxycytidineDiterpenesNF-kappa BRNA, Long Noncoding

Autor:innen und Institutionen

  • Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
  • Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
  • Department of Biochemistry, All India Institute of Medical Sciences, Guwahati, Assam, India.

Förderung

  • Indian Council of Medical Research (ICMR)
  • University Grants Commission
  • University Grants Commission of Bangladesh

Zitieren

APA

Awasthee, N., Shekher, A., Srivastava, A., & Gupta, S. C. (2026). Bharangin, A Diterpenoid, Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine Through Involvement of Long Non‐Coding RNAs and Nuclear Factor‐κB. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70097

Vancouver

Awasthee N, Shekher A, Srivastava A, Gupta SC. Bharangin, A Diterpenoid, Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine Through Involvement of Long Non‐Coding RNAs and Nuclear Factor‐κB. Clinical and Experimental Pharmacology and Physiology. 2026. doi:10.1111/1440-1681.70097

BibTeX
@article{Awasthee2026,
  author = {Awasthee, Nikee and Shekher, Anusmita and Srivastava, Ankit and Gupta, Subash Chandra},
  title = {Bharangin, A Diterpenoid, Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine Through Involvement of Long Non‐Coding RNAs and Nuclear Factor‐κB},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2026},
  doi = {10.1111/1440-1681.70097}
}
Kostenlos starten →